Abstracts tagged "population studies"

Abstract Number: 1873 • ACR Convergence 2024
Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
Snehin Rajkumar¹, Eric Yen² and Ram Singh³, ¹UCLA David Geffen School of Medicine, Irvine, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…
Abstract Number: 1879 • ACR Convergence 2024
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Mario Bautista-Vargas¹, Adrian Romero-Ocampo², Juan José Pino Vélez³, juliana Muñoz-Bedoya⁴ and Diego Rosselli⁵, ¹Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ²Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, ³Universidad de Antioquia, Envigado, Antioquia, Colombia, ⁴Universidad Corpas, Bogotá, Colombia, ⁵Pontificia Universidad Javeriana, Bogotá, Colombia
Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
Abstract Number: 1882 • ACR Convergence 2024
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
Shobhit Piplani¹, Priyanshu Jain², Vladimir Jelic³, Clement Tagoe⁴ and Beverly Johnson⁵, ¹Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, ²Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, ³Jacobi Medical Center/North Central Bronx, Bronx, NY, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Priyanka Chandratre¹, Joht Chandan², Ben Hammond³, Rasiah Thayakaran³, Samuel Cusworth³, Nicola Adderley³ and Deva Situnayake⁴, ¹The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, ²Institute of Applied Health Research, Birmingham, United Kingdom, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa-Parra¹, Andrew Hanson², Alain Sanchez-Rodriguez³, Jose Meade-Aguilar¹, Cynthia Crowson³ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Jessica Ellis¹, Anita McGrogan², Neil McHugh², Ben Mulhearn³, Eleanor Korendowych⁴, John Pauling⁵, Ian Bruce⁶, Jenny Humphreys⁷ and Sarah Skeoch¹, ¹University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Bath, Bath, United Kingdom, ³Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Manchester, Stockport, United Kingdom
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…
Abstract Number: 0239 • ACR Convergence 2023
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Michael Garshick¹, Haridarshan Patel², ada Kumar², Brian LaMoreaux², Lissa Padnick-Silver², Louis Dron³, Vinusha Kalatharan³, Vivek Verma³ and Michael Pillinger⁴, ¹NYU School of Medicine/NYU Langone Medical Center, New York, NY, ²Horizon Therapeutics, Deerfield, IL, ³Cytel Canada Inc., Vancouver, BC, Canada, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…
Abstract Number: 0251 • ACR Convergence 2023
Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study
Jie Wei¹, Hyon K. Choi², Nicola Dalbeth³, Xiaoxiao Li⁴, Changjun Li⁵, Chao Zeng⁶, Guanghua Lei⁶ and Yuqing Zhang⁷, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³University of Auckland, Auckland, New Zealand, ⁴Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁵National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁷Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Hilde Haukeland¹, Sigrid Reppe Moe¹, Cathrine Brunborg², Antonela Botea³, Nenad Damjanic⁴, Gro Wivestad⁵, Heidi Øvreås⁶, Thea Bøe⁷, Torhild Garen¹, Anniken Orre⁸, Helga Sanner⁹, Øyvind Molberg¹⁰ and Karoline Lerang⁹, ¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Betanien Hospital, Department of Rheumatology, Skien, Norway, ⁴Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, ⁵Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, ⁷Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, ⁸Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, ⁹Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, ¹⁰University of Oslo, Institute of Clinical Medicine, Oslo, Norway
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 0977 • ACR Convergence 2023
Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
Sumanth Chandrupatla¹, Kranti Rumalla² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern School of Medicine, Chicago, IL
Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Shobhit Piplani¹, Shreya Gulati², Vladimir Jelic¹, Asad Ahmed³, Sung Mi Yoon¹, Donclair Brown¹, Miroslav Radulovic¹ and Beverly Johnson⁴, ¹Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, ²Jawahar lal Nehru Medical College, New York, NY, ³SUNY Downstate, Brooklyn, NY, ⁴Albert Einstein College of Medicine, Jacobi/NCB, New York, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…
Abstract Number: 1918 • ACR Convergence 2023
Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality
Michael Manansala¹, Faria Sami², Shilpa Arora³ and Augustine Manadan¹, ¹Rush University Medical Center, Chicago, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Cook County Hospital, Chicago, IL
Background/Purpose: Sarcoidosis is multisystem autoimmune disease characterized by noncaseating granulomas which can result in significant morbidity and mortality. This study aims to identify variables associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].